Monitoring monocyte HLA-DR expression and CD4 + T lymphocyte count in dexamethasone-treated severe COVID-19 patients.
Guillaume MonneretNicolas VoirinJean-Christophe RichardMartin CourThomas RimmeléLorna GarnierHodane YonisRemy CoudereauMorgane GossezChristophe MalcusFlorent WalletMarie-Charlotte DelignetteFrederic DaillerMarielle BuissonLaurent ArgaudAnne-Claire LukaszewiczFabienne Venetnull nullPublished in: Annals of intensive care (2024)
By using standardized immunomonitoring tools available in clinical practice, it is possible to identify a subgroup of patients at high risk of mortality at the end of a 10-day dexamethasone treatment. This emphasizes the significance of integrating immune monitoring into the surveillance of intensive care patients in order to guide further immumodulation approaches.
Keyphrases
- end stage renal disease
- clinical practice
- newly diagnosed
- peripheral blood
- ejection fraction
- low dose
- high dose
- poor prognosis
- chronic kidney disease
- public health
- peritoneal dialysis
- sars cov
- prognostic factors
- dendritic cells
- early onset
- cardiovascular events
- coronary artery disease
- type diabetes
- binding protein
- clinical trial
- immune response
- patient reported outcomes
- patient reported
- combination therapy